Hikal Ltd

Hikal Ltd commenced trading on 3 Feb 2026 with a notable gap up, opening 6.84% higher than its previous close, signalling a strong start driven by positive market dynamics within the Pharmaceuticals & Biotechnology sector.

Hikal Ltd’s shares declined to a fresh 52-week low of Rs.187.1 on 2 Feb 2026, marking a significant milestone in the stock’s ongoing downward trajectory. This new low reflects sustained pressures on the company’s financial performance and market sentiment within the Pharmaceuticals & Biotechnology sector.

Hikal Ltd’s shares have declined to a fresh 52-week low, closing at Rs 189, just 0.05% above its lowest price in the past year of Rs 188.9. This marks a significant milestone in the stock’s ongoing downward trajectory, reflecting persistent pressures on the company’s financial performance and market valuation.

Hikal Ltd’s shares declined to a fresh 52-week low of Rs.188.9 today, marking a significant milestone in the stock’s ongoing downward trajectory. The pharmaceutical and biotechnology company’s stock has underperformed its sector and broader market indices, reflecting persistent pressures on its financial performance and valuation metrics.

Hikal Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 14 Nov 2025. However, the analysis and financial metrics discussed here reflect the company’s current position as of 27 January 2026, providing investors with the latest insights into the stock’s fundamentals, valuation, financial trends, and technical outlook.

Hikal Ltd’s shares touched a fresh 52-week low of Rs.190 today, marking a significant decline amid persistent downward momentum. The stock’s performance over the past year has been notably weak, reflecting a combination of financial setbacks and subdued market sentiment within the Pharmaceuticals & Biotechnology sector.

Hikal Ltd’s shares declined to a fresh 52-week low of Rs.197.15 on 23 Jan 2026, marking a significant drop amid a sustained period of underperformance. The stock has now recorded a four-day consecutive fall, losing 6.79% over this span and underperforming its sector by 1.03% today.

Hikal Ltd’s shares declined to a fresh 52-week low of Rs.198.5 today, marking a significant milestone in the stock’s ongoing downward trajectory. The pharmaceutical and biotechnology company’s shares have underperformed both its sector and the broader market, reflecting a series of financial setbacks and subdued operational metrics.

Hikal Ltd’s shares declined to a fresh 52-week low of Rs.202 on 21 Jan 2026, marking a significant milestone in the stock’s ongoing downward trajectory. The pharmaceutical and biotechnology company’s stock has underperformed its sector and broader market indices, reflecting persistent pressures on its financial and operational metrics.

Hikal Ltd’s shares touched a fresh 52-week low of Rs.207.15 today, marking a significant decline amid a series of disappointing financial results and subdued market sentiment. The stock has now recorded a seven-day consecutive fall, losing 6.38% over this period, and continues to trade below all key moving averages, reflecting persistent downward pressure.

Hikal Ltd’s shares declined to a fresh 52-week low of Rs.207.8 on 14 Jan 2026, marking a significant drop amid ongoing financial pressures and subdued performance metrics. The stock’s fall contrasts with the broader market’s modest gains, underscoring persistent challenges within the Pharmaceuticals & Biotechnology sector.

Hikal Ltd’s shares declined to a fresh 52-week low of Rs.209.3 on 12 Jan 2026, marking a significant milestone in the stock’s ongoing downward trajectory. The pharmaceutical and biotechnology company’s stock has underperformed its sector and broader market indices, reflecting a series of financial setbacks and subdued operational metrics over recent quarters.

Hikal Ltd’s shares declined to a fresh 52-week low of Rs.213.75 on 9 Jan 2026, marking a significant milestone in the stock’s ongoing downward trajectory. The pharmaceutical and biotechnology company’s stock has underperformed its sector and broader market indices, reflecting persistent pressures on its financial performance and valuation metrics.

Hikal Ltd’s shares declined sharply to a fresh 52-week low of Rs.217 on 8 Jan 2026, marking a significant drop amid ongoing underperformance relative to its sector and broader market indices.

Hikal Ltd, a key player in the Pharmaceuticals & Biotechnology sector, has experienced a notable shift in its technical momentum, with several indicators signalling a bearish trend. Despite a modest decline in price and a downgrade in its Mojo Grade to Strong Sell, the stock’s technical landscape reveals a complex interplay of signals that investors must carefully consider amid broader market conditions.

Hikal Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 14 Nov 2025. However, the analysis and financial metrics discussed here reflect the company’s current position as of 05 January 2026, providing investors with the latest insights into its performance and outlook.